SPI1 and colitis: Conversely, treatment of colitis mice with an anti-IL-9 antibody resulted in the reduced expression of IL-6, TNF-α, IL-1β, IL-10, and IL-22 in colonic tissues and decreased percentage of PU.1+ Th9 cells in the lamina propria and improved the clinical outcomes (7, 81, 83).